Hos patienter, som ikke fik methotrexat samtidig, var incidensen 12, 4% sammenlignet med 0, 6%, når adalimumab blev givet i kombination med methotrexat.
In patients not given concomitant methotrexate, the incidence was 12.4%, compared to 0.6% when adalimumab was used as add-on to methotrexate.